Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?
Dupuis-Girod S, Shovlin CL, Kjeldsen AD, Mager HJ, Sabba C, Droege F, Fargeton AE, Fialla AD, Gandolfi S, Hermann R, Lenato GM, Manfredi G, Post MC, Rennie C, Suppressa P, Sure U; ePag group; Buscarini E. Dupuis-Girod S, et al. Among authors: fargeton ae. Eur J Med Genet. 2022 Oct;65(10):104575. doi: 10.1016/j.ejmg.2022.104575. Epub 2022 Aug 5. Eur J Med Genet. 2022. PMID: 35940549 Free article.
ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
Dupuis-Girod S, Ambrun A, Decullier E, Samson G, Roux A, Fargeton AE, Rioufol C, Schwiertz V, Disant F, Chapuis F, Donazzolo Y, Paintaud G, Edery P, Faure F. Dupuis-Girod S, et al. Among authors: fargeton ae. MAbs. 2014 May-Jun;6(3):794-9. doi: 10.4161/mabs.28025. Epub 2014 Jan 30. MAbs. 2014. PMID: 24481211 Free PMC article. Clinical Trial.
Dose - response relationship of bevacizumab in hereditary hemorrhagic telangiectasia.
Azzopardi N, Dupuis-Girod S, Ternant D, Fargeton AE, Ginon I, Faure F, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Leguy-Seguin V, Rivière S, Corre R, Bailly S, Paintaud G. Azzopardi N, et al. Among authors: fargeton ae. MAbs. 2015;7(3):630-7. doi: 10.1080/19420862.2015.1022693. MAbs. 2015. PMID: 25751241 Free PMC article.
Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial.
Dupuis-Girod S, Ambrun A, Decullier E, Fargeton AE, Roux A, Bréant V, Colombet B, Rivière S, Cartier C, Lacombe P, Chinet T, Blivet S, Blondel JH, Gilbert-Dussardier B, Dufour X, Michel J, Harle JR, Dessi P, Faure F. Dupuis-Girod S, et al. Among authors: fargeton ae. JAMA. 2016 Sep 6;316(9):934-42. doi: 10.1001/jama.2016.11387. JAMA. 2016. PMID: 27599328 Clinical Trial.
Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients.
Guilhem A, Fargeton AE, Simon AC, Duffau P, Harle JR, Lavigne C, Carette MF, Bletry O, Kaminsky P, Leguy V, Lerolle N, Roux D, Lambert M, Chinet T, Bonnet D, Dupuis-Girod S, Rivière S. Guilhem A, et al. Among authors: fargeton ae. PLoS One. 2017 Nov 30;12(11):e0188943. doi: 10.1371/journal.pone.0188943. eCollection 2017. PLoS One. 2017. PMID: 29190827 Free PMC article.
Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial.
Dupuis-Girod S, Pitiot V, Bergerot C, Fargeton AE, Beaudoin M, Decullier E, Bréant V, Colombet B, Philouze P, Faure F, Letievant JC. Dupuis-Girod S, et al. Among authors: fargeton ae. Sci Rep. 2019 Aug 19;9(1):11986. doi: 10.1038/s41598-019-48502-9. Sci Rep. 2019. PMID: 31427745 Free PMC article. Clinical Trial.
Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial.
Dupuis-Girod S, Fargeton AE, Grobost V, Rivière S, Beaudoin M, Decullier E, Bernard L, Bréant V, Colombet B, Philouze P, Bailly S, Faure F, Hermann R. Dupuis-Girod S, et al. Among authors: fargeton ae. J Clin Med. 2020 Apr 26;9(5):1262. doi: 10.3390/jcm9051262. J Clin Med. 2020. PMID: 32357559 Free PMC article.
Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: A national, randomized multicenter trial.
Dupuis-Girod S, Rivière S, Lavigne C, Fargeton AE, Gilbert-Dussardier B, Grobost V, Leguy-Seguin V, Maillard H, Mohamed S, Decullier E, Roux A, Bernard L, Saurin JC, Saroul N, Faure F, Cartier C, Altwegg R, Laccourreye L, Oberti F, Beaudoin M, Dhelens C, Desvignes C, Azzopardi N, Paintaud G, Hermann R, Chinet T. Dupuis-Girod S, et al. Among authors: fargeton ae. J Intern Med. 2023 Dec;294(6):761-774. doi: 10.1111/joim.13714. Epub 2023 Aug 23. J Intern Med. 2023. PMID: 37592715 Clinical Trial.
12 results